Tom Testa, Corza Medical CEO: “We are driving a strong focus on the end-to-end customer experience by creating a robust digital ecosystem that allows us to support our customers all along their journey even as they go digital.”

After surveying the market and listening to its customers (e.g., clinicians, nurses, and hospital administrators), Corza Medical found that as companies grow and scale, there is an unfortunate shift that occurs— they shift focus away from mature product lines toward their latest technical innovations. This transforms what was once a strong partnership to ensure that existing products stay valuable into just a transactional one. That gap in the market for strong partnerships, reliable service, and dependable performance has become a strong unmet need with these mature but still critically important surgical products, technologies, and solutions. Corza Medical was formed with a mission to close that gap with a relentless focus on three elements: trusted performance with the products and technologies it deploys, remarkable service in all its customer interactions — and in doing those two well, deliver on the third element of delivering outstanding value consistently.

Corza Medical has three major global business units that align with its respective technology portfolio and capabilities — the company’s Biosurgery business unit has its innovative and state-of-the-art technology that helps control bleeding during surgery, Corza’s Wound Closure business unit has industry-leading needle technology and sutures that are essential in maintaining wound closure integrity during surgery, and finally the Ophthalmology business unit is focused on improving care through Corza’s high-performance instrumentation, surgical lenses and other innovative, trusted technologies for the global eye care community.

In conversation with Tom Testa, CEO of Corza Medical

Q. What are the challenges you had to face while developing solutions for Corza Medical? How did you overcome them?

Our first and principal Corza Core Value is putting the Customer-First. Today, with over 2,500 employees globally (and growing), a global operations infrastructure, and a combination of direct and distributor commercial teams in our global markets, ensuring that our operational engine is working seamlessly in the background so that our customers always have a remarkable experience is the challenge that we look to overcome every single day. Our global teams overcome this challenge through a strong culture of collaboration, accountability, and relentless focus on the customer experience in all our global business activities.

Q. Where do you stand as a company in the current market landscape?

We are unique as a company in what we do in the market landscape today. It is hard to find another company like ours that is as well-positioned and clinically relevant in addressing the ongoing care-setting shift towards lower acuity care (e.g., ambulatory surgical centers, clinics, and offices). While our Biosurgery business maintains a strong position in the acute care setting (e.g., hospitals), our Wound Closure and Ophthalmology businesses are well positioned to address the needs of the care setting shift to lower acuity care settings leveraging their disease-state relevance and technology portfolio. As we grow the business, we will maintain a strong focus on further strengthening that unique and differentiated position globally.

Q. How is your company structured?

Corza Medical is a global company headquartered in the U.S., with over half of our revenue coming from markets outside the U.S. We have offices and employees on all the major continents around the world, including North America, Europe, and Asia, supporting the four global business units within Corza Medical. Our extensive and successful Biosurgery business has our TachoSil product that helps to control bleeding during cardiovascular surgery and liver surgery. The indications differ from country to country, but it is a global product and well respected. Then we have our Wound Closure business focused on our suture and needle technology produced at our manufacturing center of excellence in North America. Our Ophthalmology business caters to eye care globally, from large-volume surgeries like cataract surgery to various other disease states in the front and back of the eye. Finally, we have our OEM business, leveraging our technology expertise to partner with large strategic companies and well-known brands.

Q. What does the future hold for your company and its customers? Are exciting things on the way?

The future is very exciting for all of us at Corza Medical and for our customers! There are several exciting ways that we can continue to serve our customers globally through innovation, service excellence, and digital engagement, which is one particularly exciting area. We are driving a strong focus on the end-to-end customer experience by creating a robust digital ecosystem that allows us to support our customers all along their journey even as they go digital. The world has gone digital, and our customers and clinicians have likewise gone digital in ways they’d like to interact with us. We are committed to, and are already delivering through our e-commerce channels, innovative ways to be relevant along the digital customer journey; in how our customers find us, how they learn about us, how they engage with us, and then how we continue to serve them seamlessly.

Get in touch: https://corza.com/

Meet the leaders behind the success of Corza Medical

Corza Medical is a portfolio company of funds managed by GTCR, a leading private equity firm, which helped create and build the business alongside Gregory T. Lucier. In January 2021, GTCR and Lucier simultaneously acquired and merged Surgical Specialties Corporation and the TachoSil carve-out from Takeda Pharmaceutical. GTCR believes in building value in their portfolio companies during their ownership tenure. They have been pioneers in their Leaders Strategy, which they continue to drive forward, whereby they partner with renowned industry leaders and leverage their expertise to deploy capital. For Corza Medical, the partnership was with Gregory T. Lucier, Corza’s Executive Chairman. Greg and GTCR have assembled the company with innovative technologies and top leadership, like Corza Medical CEO Tom Testa.

Tom Testa is a seasoned executive bringing more than 30 years of leadership experience, with the last 12 years focused on the medical device industry. Before becoming CEO in 2023, Tom was Chief Financial Officer of Corza Medical since its inception in 2021. Tom’s experience includes both senior financial and general management roles. He came to Corza Medical following his assignment as Vice President and General Manager of Nordson Medical, which he joined following Nordson’s acquisition of the Vention Medical Advanced Technologies business, where he was President. Tom was formerly the Chief Financial Officer of Vention Medical and GenTek, Inc., a diversified industrial holding company. Tom earned a Bachelor of Science in Chemical Engineering from the New Jersey Institute of Technology and an MBA in Finance from the Stern School of Business at New York University.

“Our technology solutions, with a legacy of trusted performance, allow Corza Medical to establish strong clinical relevance across acute care settings (e.g., hospitals, etc.) and also non-acute care settings (ambulatory surgical centers, clinics, etc.).”